News

Featured Articles

Cristalia products with Nemera’s reusable pen injector commercialized in Brazil.

Cristalia’s human growth hormone will be administered with CRISPEN®. Approved by ANVISA1, CRISPEN® is part of Nemera’s state-of-the-art pen injector platform PENDURA AD.

2023 ESG

Committed to sustainability!

25/09/2023

We’re taking another important step forward – we commit to sourcing 100% renewable electricity across all our manufacturing facilities by 2030.

2023 ESG

Nemera reinforces commitment to sustainability with first integrated ESG report

10/03/2023

Designed as a snapshot of work over the years and a look into the future, the first ESG report is a new and important step forward in our sustainability journey...

2023 ESG

The Gender Equality Index at Nemera – Year 2022

28/02/2023

The Index, is calculated from 4 to 5 indicators depending on whether the company has less or more than 250 employees and takes into account

2023 ESG

The Gender Equality Index at Nemera – Year 2023

28/02/2024

The Index, is calculated from 4 to 5 indicators depending on whether the company has less or more than 250 employees and takes into account

ESG

The Gender Equality Index at Nemera – Year 2021

25/02/2022

L’Index, se calcule à partir de 4 à 5 indicateurs selon que l’entreprise fait moins ou plus de 250 salariés et prend en compte : L’écart de rémunération femmes-hommes, L’é...

ESG

Nemera joins IPAC-RS as an Associate Member

20/10/2021

Nemera is excited to announce that it has become an Associate Member of the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS)